Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84457 trials found · Page 21 of 4223
-
Breakthrough hope for Drug-Resistant TB: shorter treatment with new pill
Disease control Not yet recruitingThis study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety, tolerability, and preliminary efficacy of acetohydroxamic acid (AHA) capsules combined with short-course regimens (BDLLfxC or BDCZ) in patients with multidrug…
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Mind-Reading chips aim to give voice and control to the paralyzed
Symptom relief Recruiting nowThis research study is being done to develop a novel brain-computer interface (BCI) technology that can enable severely paralyzed individuals to interact with the world through direct brain-control of a computer. This technology is named MindEx (for Mind Extender). It utilizes fo…
Phase: NA • Sponsor: Nader Pouratian • Aim: Symptom relief
Last updated Apr 13, 2026 20:20 UTC
-
Radical cell therapy tested for incurable autoimmune conditions
Disease control Recruiting nowA single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA U CAR T cells in patients with autoimmune diseases. 60 patients are planned to be enrolled in the dose-escalation trial.
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Apr 17, 2026 16:12 UTC
-
UCLA pioneers 'Delayed Tolerance' to free liver patients from toxic drugs
Disease control Recruiting nowThis clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed…
Phase: PHASE1, PHASE2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Apr 13, 2026 20:16 UTC
-
Zapping the spine to walk again: new hope for spinal injury patients
Disease control Recruiting nowA well-established rehabilitation strategy for improvements of standing and walking ability in persons with spinal cord injury (SCI) is step training on a motorized treadmill with body weight support. A promising intervention is stimulation of the spinal cord through the skin (tr…
Phase: NA • Sponsor: Maria Knikou, PT, MBA, PhD • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Scientists test 'Double Punch' cell therapy for tough pancreatic cancer
Disease control Recruiting nowThis is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of Claudin18.2 Targeted Activated DC combined with CAR-T therapy in patients with Advanced Pancreatic Cancer. This combination therapy activates dendritic cells (DCs) to pre…
Phase: EARLY_PHASE1 • Sponsor: Hainan Cancer Hospital • Aim: Disease control
Last updated Apr 22, 2026 05:28 UTC
-
New hope for tough pancreatic cancer: trial tests targeted drug
Disease control Recruiting nowPancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic c…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
Race against time: can a Clot-Busting drug still help stroke patients hours later?
Disease control Recruiting nowThis study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study. Part…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC
-
New hope for ALS patients: experimental drug trial seeks to slow devastating disease
Disease control ENROLLING_BY_INVITATIONThe HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen I will evaluate the safety and efficacy of a single study drug, NUZ-001, in participants with …
Phase: PHASE2, PHASE3 • Sponsor: Merit E. Cudkowicz, MD • Aim: Disease control
Last updated Apr 06, 2026 14:15 UTC
-
New drug could help women with ovarian cancer live longer without disease progression
Disease control Recruiting nowResearchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance tr…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 22, 2026 05:28 UTC
-
New immune cell therapy tested for Tough-to-Treat blood cancer
Disease control Not yet recruitingThis research project includes patients with relapsed/refractory multiple myeloma (r/r MM) who have received more than three lines of treatment, including those with secondary recurrence, SCT recurrence, and refractory cases. Through this study, we aim to preliminarily determine …
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated Apr 07, 2026 14:38 UTC
-
Scientists test 'Double-Target' cell therapy in fight against tough blood cancers
Disease control Not yet recruitingThe purpose of this clinical trial is to evaluate the safety and efficacy of CAR1922T2 T-cell therapy in participants with relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Participants will receive a single infusion of CAR1922T2 T-cells and comp…
Phase: EARLY_PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
Could a Penny-a-Day pill stop another stroke? major trial launches for brain bleed survivors
Disease control Not yet recruitingBEAT ICH will be a pragmatic, randomised, placebo-controlled, blinded, superiority clinical trial aiming to recruit 5676 patients aged ≥18 years who survive ICH and assign them 1:1 to starting antiplatelet monotherapy (Aspirin 75 mg od) versus placebo for the entire duration of t…
Phase: PHASE3 • Sponsor: Christian Medical College and Hospital, Ludhiana, India • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Immune drug trial offers new hope for women with early menopause to regain fertility
Disease control Recruiting nowSeveral autoimmune diseases such as Addison's disease are associated with failing ovarian function, known as premature ovarian insufficiency (POI), which can lead to early menopause and reduced fertility.The underlying cause of POI in these women is considered to be an immunologi…
Phase: PHASE3 • Sponsor: Angelica Lindén Hirschberg • Aim: Disease control
Last updated Apr 06, 2026 14:06 UTC
-
New hope for advanced bladder cancer patients in major trial
Disease control Recruiting nowThe study is being conducted to evaluate the efficacy of SHR-A2102 with adebrelimab versus gemcitabine in combination with cisplatin/carboplatin in previously untreated locally advanced or metastatic urothelial carcinoma.
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New hope for Tough-to-Treat rectal cancer: major trial tests powerful drug combo
Disease control Not yet recruitingThis study is a national multicenter, prospective randomized controlled Phase III clinical trial designed to investigate the potential therapeutic benefit of immunotherapy combined with total neoadjuvant therapy (TNT) and to compare the efficacy of different radiotherapy modaliti…
Phase: PHASE3 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC
-
New hope for kids with aggressive cancers: trial tests supercharged immune transplant
Disease control Recruiting nowHematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for hematologic malignancies and non-malignant diseases addit…
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Apr 17, 2026 16:12 UTC
-
Three-Drug attack on deadly lymphoma shows promise
Disease control Not yet recruitingExtranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with poor prognosis in advanced stages, with a 5-year overall survival (OS) rate of less than 30% despite asparaginase-based regimens. Preclinical and clinical evidence suggests that PD-L1 is …
Phase: PHASE2 • Sponsor: LIANG WANG • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Race to stop lung scarring before it starts in High-Risk families
Prevention Recruiting nowThis study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called …
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Prevention
Last updated Mar 30, 2026 14:33 UTC
-
CRISPR gene editing tested as new weapon against tough lung cancers
Disease control Not yet recruitingThe purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of EDB-102 Injection in patients with advanced non-small cell lung cancer (NSCLC) who have liver metastases. The study specifically targets patients harboring the EGFR-L858R mutation who h…
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 22, 2026 05:29 UTC